Cardiol Therapeutics Signs Exclusive National Supplier Agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart

Investors

Press Releases

Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation

March 05, 2020

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

January 15, 2020

Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

December 18, 2019

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to its Board of Directors

December 03, 2019

Cardiol Therapeutics comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

November 25, 2019

Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx™100

November 19, 2019

Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx™100

October 01, 2019

Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12^th

September 05, 2019

Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

July 29, 2019

Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

June 20, 2019